Human HVEM / TNFRSF14 Protein, Fc Tag (MALS verified)
分子別名(Synonym)
TNFRSF14,ATAR,HVEA,HVEM,LIGHTR,TR2,CD270
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human HVEM, Fc Tag (HVM-H5258) is expressed from human 293 cells (HEK293). It contains AA Leu 39 - Val 202 (Accession # NP_003811.2).
Predicted N-terminus: Leu 39
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 43.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
皰疹病毒進(jìn)入介質(zhì)(HVEM)也稱為TNFRSF14、TR2(TNF受體樣分子)和ATAR(另一種TRAF相關(guān)受體),是屬于TNF/NGF受體超家族的I型膜蛋白。在外周血T細(xì)胞、B細(xì)胞、單核細(xì)胞和富含淋巴細(xì)胞的各種組織中檢測到HVEM表達(dá)。HVEM的細(xì)胞外結(jié)構(gòu)域已被證明與單純皰疹病毒包膜糖蛋白D(gD)直接相互作用。兩種TNF超家族配體,包括分泌的TNFβ(淋巴毒素α)和膜蛋白LIGHT(淋巴毒素,表現(xiàn)出可誘導(dǎo)的表達(dá),并與HSV糖蛋白D競爭T淋巴細(xì)胞表達(dá)的受體HVEM),已被證明是HVEM的細(xì)胞配體。除了HVEM,LIGHT還可以與淋巴毒素αβ異三聚體的受體LTβR相互作用。HVEM LIGHT/LTβ受體配體對在免疫功能和皰疹病毒病理生物學(xué)中的作用仍有待闡明。
關(guān)鍵字: HVEM;HVEM蛋白;HVEM重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。